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BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological
evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates.
METHODS: We identified biological markers accurately detected in a simple PE examination. We analysed data from 19 patients
diagnosed with lung cancer (nine adeno-Ca, five non-small-cell Ca (not specified), four squamous-cell Ca, one large-cell Ca) and 22
patients with benign inflammatory pathologies: secondary to trauma, pneumonia or TB.
RESULTS: Pleural effusion concentrations of seven analysed biological markers were significantly lower in lung cancer patients than in
benign inflammatory patients, especially in matrix metalloproteinase (MMP)-9, MMP-3 and CycD1 (lower by 65% (Po0.000003),
40% (Po0.0007) and 34% (Po0.0001), respectively), and in Ki67, ImAnOx, carbonyls and p27. High rates of sensitivity and specificity
values were found for MMP-9, MMP-3 and CycD1: 80 and 100%; 87 and 73%; and 87 and 82%, respectively.
CONCLUSIONS: Although our results are of significant merit in both the clinical and pathogenetic aspects of lung cancer, further research
aimed at defining the best combination for marker analysis is warranted. The relative simplicity in analysing these markers in any
routine hospital laboratory may result in its acceptance as a new diagnostic tool.
British Journal of Cancer (2010) 102, 1180–1184. doi:10.1038/sj.bjc.6605607 www.bjcancer.com
Published online 9 March 2010
& 2010 Cancer Research UK
Keywords: pleural fluid; lung cancer; inflammation; pleural effusion; cytology; tumour markers
                                                 
Paramount importance lies in the correct diagnosis of pleural
effusion (PE) as benign or malignant, as PE might be the first
presenting sign of cancer, suggestive of recurrent or advanced
disease (DeCamp et al, 1997), naturally necessitating adequate
treatment and management. Malignant pleural effusion (MPE) is a
common and distressing condition seen at the advanced stage of
various malignant diseases, with the majority of cases having
exsudative character (Valde ´s et al, 1996). Although lung cancer is
the most common cause of MPE (Neragi-Miandoab, 2006), almost
all forms of cancer, including cancer of ovary and stomach,
lymphoma, Hodgkin’s and non-Hodgkin’s disease, can cause MPE
as well (Sahn, 1998). As for the formation of MPE, primary or
metastatic tumours may invade the visceral pleura, affecting the
normal resorptive flow of fluid from the parietal to the visceral
pleura (DeCamp et al, 1997) or causing increased capillary leaking
and increased fluid production (Silverberg, 1970). A blockage
in the lymphatic system anywhere between the parietal pleura
and mediastinal lymph nodes results in accumulation of fluid in
the pleural space (Meyer et al, 2004). Intrapulmonary shunt is the
main underlying reason for the arterial hypoxaemia associated
with large PE (Perpin ˜a ´ et al, 1983). Benign PE can possibly result
from inflammatory processes, as well as from left ventricular
failure, cirrhosis and haemodynamic or neoplastic conditions
(Woenckhaus et al, 2005).
The conventional cytological evaluation of pleural fluids for
differentiating benign PE from MPE is of limited diagnostic
accuracy (Garcı ´a-Bonafe ´ and Moragas, 1996; Kjellberg et al, 1997),
with relatively low sensitivity rates ranging from 43 (Ma ˚rtensson
et al, 1985) to 71% (Nance et al, 1991), averaging 58% (Motherby
et al, 1999). Diagnostic inaccuracies and a high incidence of false
negatives surely endanger patients with clinical mistreatment and
mismanagement. Increasing the low sensitivity of PE cytology
would be difficult to attain in the clinical area, as its diagnostic
accuracy depends on the volume of liquid examined, the type of
preparation and staining, the experience of the examiner and the
number of sufficient specimens investigated. Rather, analyses that
are both supplementary and complementary to cytology could
be more clinically relevant resolutions for increasing the sensitivity
rates of routine PE examinations for malignancy.
Accordingly, the investigation of tumour marker assays of
sufficient clinical specificity and sensitivity for distinguishing
between benign and malignant PEs emerged for improving the
diagnostic value of cytology. A recent meta-analysis addressing the
diagnostic accuracy of tumour markers for malignant PE found
that the sensitivity and specificity of such markers were relatively
low, ranging between 25 and 55%. Although these findings
pave the way for enhancing the diagnostic value of cytology, the
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sreported markers were unspecific to lung cancer, the main cause of
MPE, enforcing the necessity for additional investigation of more
sensitive biological markers (Liang et al, 2008).
The aim of this study was to investigate pleural fluid for various
biological markers that would allow, once supplemented to the
cytological analysis, a highly sensitive distinction between benign
and malignant PEs. As non-small-cell lung cancer (NSCCA) is the
most common cause of MPE (Neragi-Miandoab, 2006), and to
minimise the variability of the study sample and increase its
homogeneity, we compared a group of patients diagnosed with
lung cancer with patients diagnosed with non-malignant inflam-
matory pathologies.
MATERIALS AND METHODS
Patients and study design
We analysed data from a study group of 19 patients diagnosed with
lung cancer, and compared it with a group of 22 patients suffering
from various benign inflammatory pathologies. The latter group
included patients with inflammatory pathology of the pleura,
secondary to trauma, pneumonia or TB. The lung cancer group
included 12 men and 7 women with a mean age of 67.8±4.3 years
and the non-malignant group included 15 men and 7 women with a
mean age of 58.8±7.3 years (not significantly different). Among the
lung cancer group were nine patients diagnosed with adeno-Ca, five
with non-small-cell Ca (not specified), four with squamous-cell
Ca and one with large-cell Ca. No cancer cells were found in the
pleural fluid harvested from six patients, similar to all cases
of the benign group (sensitivity and specificity rates of 68 and
100%, respectively). The definitive diagnosis of malignant diseases
was verified in those six patients whose cytological analysis was
negative by further tissue analysis procedures. Pleural fluid samples
were collected and stored at  801C until further use. The protein
levels of matrix metalloproteinase (MMP)-9, MMP-3, MMP-2, p27,
Skp2, Cox-2, CyclinD1 and Ki67, as well as the levels of carbonyls
and the antioxidative capacity (IMANOX assay), were analysed. In
addition to these 10 specific markers, presumably related to cancer/
proliferation/oxidative stress, a routine analysis of the patient’s
blood and pleural fluid was performed. The routine pleural analysis
included pH, albumin, LDH, glucose, total protein, amylase and
white blood cells count (WBC). Albumin, total protein and WBC
were also analysed in the patients’ blood. Interestingly, none of the
routine parameters analysed were significantly different between
the two groups (neither in the blood nor in the pleural fluid).
Immunoreactivity assay
Pleural fluid samples were centrifuged (800 g, 10min, 41C), and
pellets were suspended in 150ml of lysis buffer (45mM HEPES,
0.4 M KCl, 1mM EDTA, 10% glycerol, pH 7.8). After 30min of
incubation at room temperature, the samples were centrifuged
(11000 g, 10min, 41C). Protein concentrations in the super-
natants were determined. A volume containing 50ng of protein
was transferred to a 1.5ml vial and all samples were brought to the
same volume of 500ml with the addition of PBS. The solutions were
mixed well and 100ml of each sample was added to ELISA-plate
wells (nunc-immunoplate; Thermo Fisher Scientific, Waltham,
MA, USA). The plate was covered and stored overnight at 41C. The
next day, each well was washed three times with 100ml PBS-Tween
solution (PBS-T, PBS containing 0.05% Tween 20) and a volume
of 100ml of 1% BSA PBS-T blocking solution (PBS containing
0.05% Tween 20 and 1% BSA) was added to each well. After 1h
incubation at room temperature, 100ml of primary antibody was
added to each well. After 2h of incubation at room temperature,
the plate was washed as described above and a volume of 100mlo f
secondary antibody was added to each well. After 2h of incubation
at room temperature, the plate was washed as described above. To
achieve colour development, we added 100ml of 3,30,5,50-tetra-
methylbenzidine solution (TMB) (Southern Biotech, Birmingham,
AL, USA) to each well. After 1–2min, we added 100ml of stopping
reagent to each well (10% sulphuric acid). Absorbencies of the
samples, representing the levels of the specific proteins examined,
were measured at 450nm, directly after the addition of the
stopping reagent, using a Zenith 200 ELISA reader (Anthos,
Eugendorf, Austria). For MMP-9 we used a polyclonal rabbit
anti-human antibody (1:1000; Sigma-Aldrich, Saint Louis, MO,
USA); for MMP-3 we used a polyclonal rabbit anti-human
antibody (1:500; Sigma-Aldrich); for MMP-2 we used a mono-
clonal rabbit anti-human antibody (1:1000; Sigma-Aldrich); for
p27 we used a polyclonal rabbit anti-human antibody (1:1000; Cell
Signaling, Danvers, MA, USA); for Cyclin D1 we used a polyclonal
rabbit anti-human antibody (1:500; Sigma-Aldrich); for Ki67 we
used a monoclonal rabbit anti-human antibody (1:1000; Acris
Antibodies, Herford, Germany); for Cox2 we used a polyclonal
rabbit anti-human antibody (1:1000; Cell Signaling); for Skp2
we used a polyclonal rabbit anti-human antibody (1:1000; Cell
Signaling); and for all assays we used a peroxidase-conjugated goat
anti-rabbit secondary antibody (1:5000; Jackson Immunoresearch,
West Grove, PA, USA).
Detection of protein oxidation (protein carbonyl assay)
An enzyme-linked immunosorbent assay (ELISA) colorimetric test
kit (BioCell Corporation, Papatoetoe, New Zealand) was used to
quantitatively measure the products of protein oxidation
(carbonyls) in pleural fluid samples. Samples were centrifuged
(800 g, 10min, 41C) and pellets were suspended in 150ml of lysis
buffer (45mM HEPES, 0.4 M KCl, 1mM EDTA, 10% glycerol, pH 7.8).
After 30min incubation at room temperature, the samples were
centrifuged (11000 g, 10min, 41C) and supernatants were stored
at  201C. On the day of the carbonyl analysis, the supernatants
were thawed and protein concentrations were determined.
A volume of 20mg was transferred to a 1.5ml vial and all samples
were brought to the same volume of 100ml with the addition of
water of high-pressure liquid chromatography grade. We added
0.8 volumes of ice-cold 28% trichloroacetic acid, mixed well, and
after 10min of incubation on ice , the tubes were centrifuged
(10000 g, 3min, 41C). Supernatants were carefully aspirated
without disturbing the pellet. A volume of 5ml of EIA buffer (1 M
phosphate solution containing 1% BSA, 4 M NaCl, 10mM EDTA
and 0.1% sodium azide) and 15ml of diluted 2,4-dinitrophenol
(DNP) solution were added to samples according to the
manufacturer’s instructions. After 45min of incubation at room
temperature, 5ml of each sample was taken to a parallel set of
1.5ml vials containing 1ml EIA buffer. The solutions were mixed
well and 200ml of each sample was added to ELISA-plate wells.
The plate was covered and stored overnight at 41C. The next day,
the plate was washed three times with EIA buffer (250ml per well)
and 250ml of diluted blocking solution (provided by the
manufacturer) was added to each well. After 30min incubation
at room temperature, the wells were washed as described above
and 200ml of diluted anti-DNP-biotin antibody was added to each
well. The plate was incubated for 1h at 371C. After incubation, the
plate was washed and 200ml of diluted streptavidin-HRP was
added to each well. After 1h incubation at room temperature,
the plate was washed as described above. To achieve colour
development, we added 200ml of chromatin reagent (provided by
the manufacturer) to each well. After 5min, we added 100mlo f
stopping reagent to each well. The absorbencies of samples were
measured at a wavelength of 450nm directly after the addition of
the stopping reagent, using a Zenith 200 ELISA reader (Anthos).
To quantify absorbance values, we performed the same procedure
for standard and control samples provided by the manufacturer,
and created a standard curve.
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sAntioxidative capacity (IMANOX assay)
An ELISA colorimetric test kit (Immundiagnostik AG, Bensheim,
Germany) was used to quantitatively measure the total antioxi-
dative capacity in pleural fluid samples, as previously described
(Hershkovich et al, 2007). Briefly, a defined amount of exogenous
hydrogen peroxide (H2O2) was added to the samples, which was
partly eliminated by the pleural fluid antioxidants. The residual
H2O2 was determined by an enzymatic reaction involving the
conversion of TMB to a colorimetric product. After the addition
of a stop solution to the samples, absorbance was measured at
450nm, using a Zenith 200 ELISA reader (Anthos). To quantify
the absorbance values, we used a calibrator provided by the
manufacturer.
Statistical analysis
The levels of various markers were evaluated in pleural fluid
samples, and mean s.d. (STD and mean standard error (s.e.) values
were analysed and compared with the two sample t-tests for
differences in means. The criterion for statistical significance was
Po0.05. The correlations between the levels of various markers
in the pleural fluid samples were analysed using the Pearson
correlation analysis. A correlation matrix of estimators was
used to analyse the correlation coefficients between parameters.
For classification analysis, cutoff values were calculated as
mean±1s.d. of the non-malignant patients. Sensitivity and
specificity values were calculated as the fraction of observations
that was correctly classified.
RESULTS
Pleural fluid markers
Pleural fluid marker analysis revealed highly significant differences
in the levels of seven of the analysed markers between benign
and lung cancer patients (Table 1, Figure 1): the concentrations of
all seven markers, MMP-9, MMP-3, CycD1, Ki67, ImAnOx,
carbonyls and p27, were lower in cancer patients by 9–65%. In
benign patients, the pleural fluid mean (±s.e.) concentrations (OD
values) of MMP-9, MMP-3, CycD1, Ki67, ImAnOx, carbonyls and
p27 were 0.426±0.037, 0.202±0.024, 0.799±0.041, 0.294±0.031,
205.9±12.3, 0.802±0.032 and 0.597±0.031, respectively. The
decreases in pleural MMP-9, MMP-3 and CycD1 were profound
and highly significant, by 65%, P¼0.000003; by 40%, P¼0.0007;
and by 34%, P¼0.0001. The mean concentration of Ki67 was
lower in the PE of cancer patients by 31% (P¼0.028) and that
of ImAnOx, carbonyls and p27 was lower by 20% (P¼0.012),
17% (P¼0.025) and by 9% (P¼0.025), respectively (Table 1).
Interestingly the pleural concentrations of the other three markers
analysed were also lower in the lung cancer group than in the
benign group, yet not in a statistically significant manner. Thus,
the concentrations of MMP-2, Skp-2 and Cox-2 were reduced by
23% (P¼0.238), 8% (P¼0.160) and 10% (P¼0.132), respectively.
The sensitivity values of these seven analysed markers were in
the range of 33–100%, whereas the specificity values were in the
range of 77–90% (Table 1).
Sensitivity and specificity values were especially high for MMP-9
(100 and 80%, respectively) and CycD1 (82 and 87%, respectively).
High specificity values were also found for IMANOX and MMP-3
(90 and 87%, respectively). The positive likelihood ratio (LRþ),
the negative likelihood ratio (LR ) and the diagnostic odds ratio
values of MMP-3 and of IMANOX were 6.9, 0.1 and 62.7, respec-
tively. These values for CycD1 were 6.3, 0.2 and 31.5, respectively.
The LRþ and LR  values of MMP-9 were 5 and 0, respectively.
Multiple significant (o 0.4 or r40.4) correlations were
demonstrated among all seven markers, each with some of the
others. The most significant correlations were demonstrated
between MMP-9 and CycD1 (0.69); MMP-9 and MMP-3 (0.68);
and MMP-9 and Ki67 (0.62). Also quite high were the significant
correlations between Ki67 and p27 (0.57) and between Ki67 and
carbonyls (0.52) (Table 2).
Cytological and biochemical examination
The 19 cancer patients included the following three subgroups:
nine patients with a definitive diagnosis of NSCCA/Adeno Ca/SCC;
four patients with a non-definitive malignant diagnosis or a
suspected malignant diagnosis; and six patients with a benign
cytological diagnosis identical to that obtained in the 22 benign
patients. In all 19 cancer patients, the final diagnosis was made on
tissue analysis obtained in a biopsy or in a fine-needle aspiration
procedure. The non-malignant cells observed in these six false
negatives and in the 22 truly benign cases included mesothelial
cells, lymphocytes, leukocytes, granulocytes and histiocytes.
The pleural biochemical analysis revealed the following mean±
STD values in the control group: Ph ¼7.4±0.2, albumin¼
2±0.9 (mgl
 1), LDH¼172±61 (IUl
 1), glucose¼129±67 (mg per
100ml), total protein¼3.8±1.4 (mg per 100ml) and amylase¼
30.4±16.9 (10
 2IUl
 1). WBC was 5.6±3.2. As previously
mentioned, these values were not statistically different from those
found in cancer patients.
Table 1 Statistical analysis of seven analysed parameters
Parameter
% Of change (out





MMP 9  65 0.000003 80 100
MMP 3  40 0.0007 87 73
p27  9 0.025 80 33
Carbonyls  17 0.025 80 38
IMANOX  20 0.012 90 58
Cyclin D1  34 0.0001 87 82
Ki67  31 0.028 77 50
Abbreviations: MMP 9¼matrix metalloproteinase-9; MMP 3¼matrix metallo-
proteinase-3; IMANOX¼antioxidative capacity. The concentrations of the seven
parameters that were found to be significantly lower in the pleural fluid of lung cancer
patients as compared with non-malignant patients. The following were calculated:
percentage of change in the mean levels of each parameter, statistical significance of








































Figure 1 Meanþs.e. levels of the seven significantly altered parameters
in the pleural fluid of lung cancer patients (cancer) compared with benign
inflammatory patients (control), presented as a percentage of controls
(*Po0.05; **Po0.01).
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In this study, we examined lung NSCCA patients as they comprise
the largest lung cancer group (85% of all cases), owing to the
fact that lung cancer is the most common cause of MPE
(Neragi-Miandoab, 2006). Furthermore, investigation of patients
with a common pathology contributed to the homogeneity of the
study sample, as accurate and early diagnosis of their staging may
promote effective clinical management. Such a diagnosis based on
a simple PE examination may be achieved rapidly and may
substantially reduce the rate of accompanying morbidity.
The most important result in this study involves the pleural fluid
concentrations of seven analysed biological markers, found to be
significantly lower in lung cancer patients than in benign
inflammatory patients. This was especially true for MMP-9,
MMP-3 and CycD1, the concentrations of which in cancer patients
were lower by 65 (Po0.000003), 40 (Po0.0007) and 34%
(Po0.0001), respectively. High rates of sensitivity and specificity
were found for these markers, which for MMP-9, MMP-3 and
CycD1 were 80 and 100%; 87 and 73%; and 87 and 82%,
respectively. We thus believe that the demonstrated results
are of significant merit with respect to both the clinical and
pathogenesis-related aspects of lung cancer.
As for the clinical aspect, the significant differences demon-
strated in pleural markers of lung cancer and benign patients may
be used as a diagnostic tool, which is of special importance for
patient staging and management. Accordingly, PE analysis may
become a valuable rapid-diagnosis tool, saving many unnecessary
biopsies and hospital/outpatient clinic visits, especially in light of
the poor sensitivity of the currently available pleural cytological
examination. It is well established that the merit of any
compositional analysis is further augmented when a concurrent
analysis is performed simultaneously for several markers, thus
reaching higher sensitivity and specificity rates (Shpitzer et al,
2009). For example, in this study, the specificity rate of the PE
analysis reached 100% when the analysis included all markers
simultaneously, rather than one.
Along this line of thought, a patient with a negative cytological
finding and a pleural-marker profile supporting benign disease
would receive a different treatment than a patient with a negative
cytological finding but with a pleural-marker analysis supporting
lung cancer. In the latter case, the clinician will have a higher index
of suspicion and would have sufficient grounds for requesting a
repeat cytological analysis to reassess and consequently confirm
the patient’s clinical condition.
As for the pathogenesis-related merit of these findings, it is
noteworthy that never before had the currently reported markers
been concomitantly analysed in pleural fluid and most of them had
never been examined in PE at all. To our knowledge, only MMP-2
and MMP-9 were previously analysed in the pleural fluid of lung
cancer and benign inflammatory patients (Kotyza et al, 2004;
Di Carlo et al, 2005, 2007; Iglesias et al, 2005; Park et al, 2005;
Vatansever et al, 2009). We decided to analyse these markers as
they belong to three different marker groups that may be related to
cancer and/or to inflammatory diseases. p27, Skp2, Cox2, CycD1
and Ki67 are considered as tumour and/or proliferation markers
(Huang et al, 2003; Siggelkow et al, 2004; Adjei, 2005; Vig-Varga
et al, 2006; Garg et al, 2008; Park et al, 2008; Chang et al, 2009;
Meeran et al, 2009; Mukhopadhyay et al, 2009), ImAnOx and
carbonyls are oxidative markers (Nystro ¨m, 2005; Bahar et al, 2007)
and MMP-9, -3 and -2 are MMPs that are expressed in various
pathological processes such as inflammation and cancer and also in
response to infections (Korpos et al, 2009; Oikonomidi et al, 2009;
Vanlaere and Libert, 2009). Enhanced oxidative stress characterises
both inflammation and cancer; all other markers analysed were also
shown previously to be associated with inflammation, as well as
with oxidative stress, presumably mediated through the activation
of NF-kB (Huang et al, 2003; Vig-Varga et al, 2006; Park et al, 2008;
Gonda et al, 2009; Karalis et al, 2009; Ku et al, 2009; Perricone et al,
2009; Vı ´ctor et al, 2009). Interestingly, the significantly altered
markers correlated among themselves (Table 2), indicating that
they were all associated with each other, prompting hypothesis that
they might belong to a single biological network that, when fully
understood, may be used for the development of drugs related to
lung cancer. Alternatively, they may all share another feature that
is not related to a single biological pathway but rather to a
single general condition, affecting the cancer vs benign groups in
a different manner. Such a condition may be related to the time
period of the existing pathology, that is, its chronicity, or to the
volume of the exudates effused. Hence, if the volume of the PE
medium (transudate transfused) analysed is larger in cancer
patients, one would expect all the markers analysed to be signi-
ficantly diluted and for their concentrations to be significantly
reduced. Support for this suggestion may be found in the fact that
all 10 different markers analysed were lower in the cancer group,
although this difference did not always reach statistical significance.
Regardless of the mechanism involved, the clinical significance
of the presented results is substantial. Being able to significantly
improve the rapidity and sensitivity of the PE examination for
diagnosis and staging of NSCCA patients is of paramount
importance. In spite of the relatively high statistically significant
P-values obtained, further research analysing a larger group
of patients is warranted, as the number of patients currently
examined is rather limited. Further research aimed at finding other
sensitive biological markers in PE and for defining the best
combination for marker analysis is warranted as well. The relative
ease in performing the analysis of these markers in any hospital
laboratory may turn such an analysis into a popular new
diagnostic tool in the clinical setup.
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